Fingerprint
Dive into the research topics of 'First-line pembrolizumab versus dabrafenib/trametinib treatment for BRAF V600–mutant advanced melanoma'. Together they form a unique fingerprint.- Sort by
- Weight
- Alphabetically
First-line pembrolizumab versus dabrafenib/trametinib treatment for BRAF V600–mutant advanced melanoma
Chang Gon Kim, Miso Kim, Jieon Hwang, Seung Tae Kim, Minkyu Jung, Kyoo Hyun Kim, Kyung Hwan Kim, Jee Suk Chang, Woong Sub Koom, Mi Ryung Roh, Kee Yang Chung, Tae Min Kim, Sang Kyum Kim, Jeeyun Lee, Sang Joon Shin
Research output: Contribution to journal › Article › peer-review
1
Citation
(Scopus)